EXHIBIT 10.7

Note:  Portions of this exhibit marked with "X's" have been omitted pursuant to
       a request for confidentiality under Rule 24b-2 of the Securities Exchange
       Act of 1934, as amended. A copy of this exhibit in its entirety has been
       filed separately with the Securities and Exchange Commission.

                                                                     EXHIBIT A-1

THIS SECURITY IS SUBJECT TO THE PROVISIONS OF THE AMENDED AND RESTATED
INVESTMENT AND MASTER STRATEGIC RELATIONSHIP AGREEMENT DATED AS OF OCTOBER 9,
1997 BETWEEN THE ISSUER AND SYNTHELABO AND MAY NOT BE SOLD OR TRANSFERRED EXCEPT
IN ACCORDANCE THEREWITH. A COPY OF SUCH AGREEMENT IS ON FILE AT THE OFFICE OF
THE CORPORATE SECRETARY OF THE ISSUER. THIS SECURITY WAS SOLD IN A PRIVATE
PLACEMENT, WITHOUT REGISTRATION UNDER THE SECURITIES ACT OF 1933, AND MAY BE
OFFERED OR SOLD ONLY IF REGISTERED UNDER THE SECURITIES ACT OF 1933 OR IF AN
EXEMPTION FROM REGISTRATION IS AVAILABLE.


                         -------------------------------

                               ANGEION CORPORATION

                          COMMON STOCK PURCHASE WARRANT

                                1,350,845 Shares

         Capitalized terms used and not otherwise defined in this Common Stock
Purchase Warrant (this "Warrant") shall have the respective meanings assigned to
them in the Amended and Restated Investment and Master Strategic Relationship
Agreement dated as of the 9th day of October, 1997, between Angeion Corporation,
a Minnesota corporation having its executive offices and principal place of
business at 3650 Annapolis Lane, Minneapolis, Minnesota 55447 (the "Company"),
and Synthelabo, a French societe anonyme (the "Holder"), as the same may be
supplemented, modified, amended, renewed or restated from time to time (the
"Purchase Agreement").

         The Company does hereby certify and agree that, for value received, the
Holder, its successors and assigns, hereby is entitled to purchase from the
Company 1,350,845 duly authorized, validly issued, fully paid and non-assessable
shares of Common Stock, par value $0.01 per share ("Common Stock"), of the
Company (the "Exercise Quantity") upon the terms and subject to the provisions
of this Warrant.

Section 1.        Price and Exercise of Warrant.

         1.1 Term of Warrant. This Warrant shall be exercisable for the period
commencing on the date hereof and ending at 4:30 p.m., New York City time, on
the fourth anniversary of the date hereof (the "Expiration Date").

         1.2 Exercise Price. The price per share at which the shares of Common
Stock

<PAGE>


issuable upon exercise of this Warrant (the "Warrant Shares") shall be $6.6625
per share (the "Warrant Price") and shall be subject to downward adjustment
(which adjustments shall supercede any prior lesser adjustments pursuant to
paragraphs (c) or (d) of Section 4 below) to a price equal to one hundred thirty
percent (130%) of the XXXXXXXXXXXXXXXXXXXXXXXXX in the event of the issuance of
Supplemental Shares as contemplated by Section 2.1(e) of the Purchase Agreement.

         1.3 Exercise of Warrant. (a) This Warrant may be exercised, in whole or
in part, upon surrender to the Company at its offices at 3650 Annapolis Lane,
Minneapolis, Minnesota of the certificate or certificates evidencing this
Warrant to be exercised, together with the form of election to exercise attached
hereto as Exhibit A duly completed and executed, and upon payment to the Company
of the Warrant Price for the number of Warrant Shares in respect of which this
Warrant is then being exercised. Payment of the aggregate Warrant Price may be
made in cash, by certified or bank check or by wire transfer.

                  (b) Subject to Section 2 hereof, upon such surrender of this
Warrant, and the duly completed and executed form of election to exercise, and
payment of the Warrant Price as aforesaid, the Company shall cause to be issued
and delivered with all reasonable dispatch (and in any event within five
business days thereafter) to the Holder or such other person as the Holder may
designate in writing a certificate or certificates for the number of full shares
of Common Stock so purchased upon the exercise of this Warrant. Such certificate
or certificates shall be deemed to have been issued and any person so designated
to be named therein shall be deemed to have become a holder of record of such
shares of Common Stock as of the date of the surrender of this Warrant, and the
duly completed and executed form of election to exercise, and payment of the
Warrant Price, as aforesaid; provided, however, that if, at the date of
surrender of this Warrant and payment of the Warrant Price, the transfer books
for the shares of Common Stock purchasable upon the exercise of this Warrant
shall be closed, the certificates for the shares of Common Stock shall be
issuable as of the date on which such books shall next be opened (whether before
or after the Expiration Date), and, until such date, the Company shall be under
no duty to cause to be delivered any certificate for such shares of Common Stock
or for shares of such other class of stock. If this Warrant is exercised in
part, a new Warrant certificate of the same tenor and for the number of Warrant
Shares not exercised shall be executed by the Company.

         1.4 Fractional Interests. The Company shall not be required to issue
fractions of shares of Common Stock on the exercise of this Warrant. If any
fraction of a share of Common Stock would be issuable upon the exercise of this
Warrant (or any portion thereof), the Company shall purchase such fraction for
an amount in cash equal to the same fraction of the last reported sale price of
the Common Stock on the NASDAQ National Market System or any other national
securities exchange on which the Common Stock is then listed.

Section 2.        Exchange and Transfer of Warrant.

                  (a) This Warrant may be exchanged for two or more Warrants
entitling

<PAGE>


the Holder thereof to purchase the same aggregate Exercise Quantity at the
Exercise Price per share and otherwise having the same terms and provisions as
this Warrant. The Holder may request such an exchange by surrender of this
Warrant to the Company, together with a written exchange request specifying the
desired number of Warrants and allocation of the Exercise Quantity purchasable
under the existing Warrant. Within two business days after the Company's receipt
of this Warrant and such an exchange request, the Company will issue and deliver
such new Warrants to the Holder in the amounts and with the allocations
requested.

                  (b) Subject to the restrictions set forth in Section 4.2(d) of
the Purchase Agreement, this Warrant from time to time may be transferred, in
whole or in part, by the Holder or any duly authorized representative of the
Holder. A transfer may be registered with the Company by submission to it of
this Warrant, together with the annexed Assignment Form attached hereto as
Exhibit B duly completed and executed. Within two business days after the
satisfaction by the Holder of the conditions to such transfer set forth in such
Section 4.2(d) and the Company's receipt of this Warrant and the Assignment Form
so completed and executed, the Company will issue and deliver to the transferee
a new Warrant representing the portion of the Exercise Quantity transferred at
the same Exercise Price per share and otherwise having the same terms and
provisions as this Warrant, which the Company will register in the new holder's
name. In the event of a partial transfer of this Warrant, the Company shall
concurrently issue and deliver to the transferring holder a new Warrant that
entitles the transferring holder to purchase the balance of the Exercise
Quantity not so transferred and that otherwise is upon the same terms and
conditions as this Warrant. Upon the due delivery of this Warrant for transfer,
the transferee holder shall be deemed for all purposes to have become the holder
of the new Warrant issued respecting the Exercise Quantity transferred,
effective immediately prior to the close of business on the date of such
delivery, irrespective of the date of actual delivery of the new Warrant
representing the Exercise Quantity transferred.

                  (c) In the event of the loss, theft or destruction of this
Warrant, the Company shall execute and deliver an identical new Warrant to the
Holder in substitution therefor upon the Company's receipt of (i) evidence
reasonably satisfactory to the Company of such event and (ii) if requested by
the Company, an indemnity agreement reasonably satisfactory in form and
substance to the Company. In the event of the mutilation of or other damage to
this Warrant, the Company shall execute and deliver an identical new Warrant to
the Holder in substitution therefor upon the Company's receipt of the mutilated
or damaged Warrant.

                  (d) The Company shall pay all costs and expenses incurred in
connection with the exercise, exchange, transfer or replacement of this Warrant,
including, without limitation, the costs of preparation, execution and delivery
of a new Warrant and of stock certificates representing all Warrant Shares;
provided, however, that the Holder shall pay all stamp and other transfer taxes
payable in connection with the transfer or replacement of this Warrant.

<PAGE>


Section 3.        Certain Covenants.

                  (a) The Company shall at all times reserve for issuance and
keep available out of its authorized and unissued shares of Common Stock, solely
for the purpose of providing for the exercise of this Warrant, such number of
shares of Common Stock as shall from time to time be sufficient therefor.

                  (b) The Company will not, by amendment of its articles of
incorporation or through any reorganization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action,
avoid or seek to avoid the observance or performance of any of the terms of this
Warrant. Without limiting the foregoing, the Company (i) will not increase the
par value of any shares of capital stock receivable upon the exercise of this
Warrant above the amount payable therefor upon such exercise, and (ii) will take
all such action as may be necessary or appropriate in order that the Company may
validly and legally issue fully paid and nonassessable shares of capital stock
upon the exercise of this Warrant.

Section 4.        Adjustment of Warrant Price and Number of Warrant Shares.

         The Warrant Price in effect at any time and the number and kind of
securities purchasable upon the exercise of this Warrant shall be subject to
adjustment from time to time upon the occurrence of certain events, as
hereinafter provided.

                  (a) In case the Company shall hereafter (i) pay a dividend or
make a distribution on its Common Stock in shares of its Common Stock, (ii)
subdivide its outstanding Common Stock, (iii) combine its outstanding Common
Stock into a smaller number of shares, or (iv) issue any shares by
reclassification of its Common Stock (including any such reclassification in
connection with a consolidation or merger in which the Company is the continuing
corporation), the Warrant Price in effect at the time of the record date for
such dividend or distribution or the effective date of such subdivision,
combination or reclassification shall be proportionately adjusted so that the
Holder, upon exercise of this Warrant after such date, shall be entitled to
receive the aggregate number and kind of shares of Common Stock which, if this
Warrant had been exercised immediately prior to such record date, it would have
owned upon such exercise and been entitled to receive upon such dividend,
distribution, subdivision, combination or reclassification.

                  (b) In case the Company shall hereafter distribute to all
holders of its Common Stock shares of stock other than Common Stock, evidences
of its indebtedness or assets (excluding cash dividends or distributions out of
retained earnings and dividends or distributions referred to in paragraph (a)
above), or any rights, warrants or options to subscribe for or purchase shares
of Common Stock (or securities convertible into, exercisable for or exchangeable
for shares of Common Stock) (excluding those referred to in paragraph (c)
below), then in each such case the Warrant Price in effect thereafter shall be
determined

<PAGE>


by multiplying the Warrant Price in effect immediately prior to the date of such
issuance by a fraction, the numerator of which shall be the total number of
outstanding shares of Common Stock multiplied by the
XXXXXXXXXXXXXXXXXXXXXXXXXXXX, less the then fair market value (as determined in
good faith by the Company's board of directors) of said shares of stock, assets
or evidences of indebtedness so distributed or of such rights or warrants, and
the denominator of which shall be the total number of outstanding shares of
Common Stock multiplied by XXXXXXXXXXXXXXXXXX. Such adjustments shall be made
whenever any such distribution is made and shall become effective immediately
after the record date for the determination of shareholders entitled to receive
such distribution.

                  (c) In case the Company shall hereafter issue shares of its
Common Stock or securities (including options, warrants or rights) convertible
into, exchangeable for or exercisable for shares of Common Stock, such shares of
Common Stock or securities convertible into, exchangeable for or exercisable for
shares of Common Stock being herein called "Company Securities") at a price per
share that is less than XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX at any time during the
Initial Anti-Dilution Period (as defined below), the Warrant Price shall be
adjusted immediately thereafter so that it shall equal the price determined by
multiplying the Warrant Price in effect immediately prior thereto by a fraction,
(x) the numerator of which shall be the sum of the number of shares of Common
Stock outstanding immediately prior to the issuance of such additional Company
Securities pursuant to such offering plus the number of shares of Common Stock
which the aggregate consideration received for the issuance of such additional
shares would purchase at such XXXXXXXXXXXXXXXXXXXXXXX, and (y) the denominator
of which shall be the number of shares of Common Stock outstanding immediately
after the issuance of such additional shares pursuant to such offering. Such
adjustment shall be made successively whenever such an issuance is made.

                  (d) In case the Company shall hereafter issue any Company
Securities (excluding securities issued in transactions described in paragraph
(c) above) at an effective price per share less than the
XXXXXXXXXXXXXXXXXXXXXXX, the Warrant Price shall be adjusted immediately
thereafter so that it shall equal the price determined by multiplying the
Warrant Price in effect immediately prior thereto by a fraction, (x) the
numerator of which shall be the sum of the number of shares of Common Stock
outstanding immediately prior to the issuance of such additional Company
Securities pursuant to such offering plus the number of shares of Common Stock
which the aggregate consideration received for the issuance of such additional
shares would purchase at the XXXXXXXXXXXXXXXXXXXXX, and (y) the denominator of
which shall be the number of shares of Common Stock outstanding immediately
after the issuance of such additional shares pursuant to such offering. Such
adjustment shall be made successively whenever such an issuance is made.

                  (e) Whenever the Warrant Price payable upon exercise of this
Warrant is adjusted pursuant to paragraphs (a), (b), (c) and (d) above, the
number of Warrant Shares purchasable upon exercise of this Warrant shall
simultaneously be adjusted by multiplying the

<PAGE>


number of Warrant Shares initially issuable upon exercise of this Warrant by the
Warrant Price in effect as of the date of this Warrant and dividing the product
so obtained by the Warrant Price, as adjusted.

                  (f) Anything herein to the contrary notwithstanding:

                  (i) (A) The Company shall not be required to make any
         adjustment contemplated under paragraph (c) in the case of: (A) the
         issuance of shares of Common Stock upon the sale, issuance or exercise
         in whole or in part of the warrants to purchase shares of Common Stock
         issued pursuant to the Purchase Agreement; (B) the issuance of shares
         of Common Stock or any other securities which may now or hereafter be
         granted or exercised under any of the Company's compensatory benefit
         plans (regardless of whether such shares of Common Stock or other
         securities are issued to employees, directors, consultants or others of
         the Company or the joint venture established pursuant to the Limited
         Liability Company Operating Agreement of Angellan Medical Systems, LLC
         (the "U.S. Joint Venture Agreement")) (the "Plans") and such other
         employee benefit arrangements, contracts or plans as are recommended by
         the management of the Company and approved by its board of directors
         (adjusted appropriately for stock splits, stock combinations or stock
         dividends); (C) the issuance or sale of shares of Common Stock or
         convertible securities upon the exercise of any rights or warrants to
         subscribe for or purchase, or any options for the purchase of, Common
         Stock or convertible securities outstanding on the date of the Purchase
         Agreement, except as set forth in Schedule 2.4(f)(i)(A)(C) of the
         Purchase Agreement; (D) the issuance or sale of shares of Common Stock
         upon conversion or exchange of any convertible securities or exercise
         of any options, warrants or other purchase rights, if a prior
         antidilution adjustment was made or required to be made hereunder upon
         the issuance, sale (or grant with respect to options) of such
         convertible securities, options, warrants or other purchase rights; (E)
         the issuance of shares of Common Stock in connection with a bona fide
         merger, acquisition (including without limitation, acquisition of a
         third party's assets, products, technology or other rights) or other
         similar transaction involving the Company or a subsidiary of the
         Company if the board of directors of the Company has obtained a
         fairness opinion with respect to the issuance of such Common Stock from
         a nationally or regionally recognized investment banking firm
         indicating the financial terms of such merger, acquisition or other
         similar transaction are fair to the Company when taken as a whole; or
         (F) the issuance of any Company Securities in any transaction which is
         part of the formation of a strategic relationship or joint venture
         between the Company and a third party if the board of directors of the
         Company has obtained a fairness opinion with respect to the issuance of
         such Company Securities from a nationally or regionally recognized
         investment banking firm indicating that the financial terms of such
         strategic relationship, joint venture or other similar relationship or
         venture are fair to the Company when taken as a whole.

<PAGE>


                           (B) The Company shall not be required to make any
                  adjustment contemplated under paragraph (d) in the case of:
                  (A) the issuance of shares of Common Stock upon the sale,
                  issuance or exercise in whole or in part of the warrants to
                  purchase shares of Common Stock issued pursuant to the
                  Purchase Agreement; (B) the issuance of shares of Common Stock
                  or any other securities which may now or hereafter be granted
                  or exercised under any of the Plans and such other employee
                  benefit arrangements, contracts or plans as are recommended by
                  the management of the Company and approved by its board of
                  directors (adjusted appropriately for stock splits, stock
                  combinations or stock dividends); (C) the issuance or sale of
                  shares of Common Stock or convertible securities upon the
                  exercise of any rights or warrants to subscribe for or
                  purchase, or any options for the purchase of, Common Stock or
                  convertible securities outstanding on the date of the Purchase
                  Agreement, except as set forth in Schedule 2.4(f)(i)(A)(C) of
                  the Purchase Agreement; (D) the issuance or sale of shares of
                  Common Stock upon conversion or exchange of any convertible
                  securities or exercise of any options, warrants or other
                  purchase rights, if a prior antidilution adjustment was made
                  or required to be made hereunder upon the issuance, sale (or
                  grant with respect to options) of such convertible securities,
                  options, warrants or other purchase rights; (E) the issuance
                  of shares of Common Stock in connection with a bona fide
                  merger, acquisition (including without limitation, acquisition
                  of a third party's assets, products, technology or other
                  rights) or other similar transaction involving the Company or
                  a subsidiary of the Company if the board of directors of the
                  Company has obtained a fairness opinion with respect to the
                  issuance of such Common Stock from a nationally or regionally
                  recognized investment banking firm indicating the financial
                  terms of such merger, acquisition or other similar transaction
                  are fair to the Company when taken as a whole; (F) the
                  issuance of any Company Securities in any transaction which is
                  part of the formation of a strategic relationship or joint
                  venture between the Company and a third party if the board of
                  directors of the Company has obtained a fairness opinion with
                  respect to the issuance of such Company Securities from a
                  nationally recognized investment banking firm indicating that
                  the financial terms of such strategic relationship, joint
                  venture or other similar relationship or venture are fair to
                  the Company when taken as a whole; or (G) the issuance of
                  shares of Common Stock in connection with a bona fide private
                  placement transaction not involving purchasers or placement
                  agents affiliated with the Company if (1) the discount to
                  market is not greater than 15% and (2) the Company has
                  obtained a fairness opinion with respect to the issuance
                  thereof from a nationally or regionally recognized investment
                  banking firm that the financial terms of such transaction are
                  fair to the Company when taken as a whole.

<PAGE>


         (ii) The Company shall not be required to make any adjustment
         contemplated under paragraph (c) or (d) with respect to any Future
         Financing (as defined below) if the Investor exercises its right to
         increase or maintain its stock ownership with respect to such Future
         Financing pursuant to the Purchase Agreement.

         (iii) The provisions of paragraphs (c) and (d) above shall terminate
         and have no further force and effect upon the Investor's Rights
         Termination Date as such term is defined in the U.S. Joint Venture
         Agreement.

                  (g) The number of shares of Common Stock outstanding at any
given time for purposes of the calculations under paragraphs (c) and (d) shall
be subject to the following rules:

         (i) In case of (1) the sale by the Company for cash (or as a component
         of a unit being sold for cash) of any rights or warrants to subscribe
         for or purchase, or any options for the purchase of, Common Stock or
         any securities convertible into or exchangeable for Common Stock
         without the payment of any further consideration other than cash, if
         any (such securities convertible, exercisable or exchangeable into
         Common Stock being herein called "Convertible Securities"), or (2) the
         issuance by the Company, without the receipt by the Company of any
         consideration therefor, or any rights or warrants to subscribe for or
         purchase, or any options for the purchase of, Common Stock or
         Convertible Securities, in each case, if (and only if) the
         consideration payable to the Company upon the exercise of such rights,
         warrants or options shall consist of cash, whether or not such rights,
         warrants or options, or the right to convert or exchange such
         Convertible Securities, are immediately exercisable, and the price per
         share for which Common Stock is issuable upon the exercise of such
         rights, warrants or options or upon the conversion or exchange of such
         Convertible Securities (determined by dividing (x) the minimum
         aggregate consideration payable to the Company upon the exercise of
         such rights, warrants or options, plus the consideration, if any,
         received by the Company for the issuance or sale of such rights,
         warrants or options, plus, in the case of such Convertible Securities,
         the minimum aggregate amount of additional consideration, other than
         such Convertible Securities, payable upon the conversion or exchange
         thereof, by (y) the total maximum number of shares of Common Stock
         issuable upon the exercise of such rights, warrants or options or upon
         the conversion or exchange of such Convertible Securities issuable upon
         the exercise of such rights, warrants or options) is less than
         XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX, on the date of the issuance or sale
         of such rights, warrants or options, then the total maximum number of
         shares of Common Stock issuable upon the exercise of such rights,
         warrants or options or upon the conversion or exchange of such
         Convertible Securities (as of the date of the issuance or sale of such
         rights, warrants or options) shall be deemed to be outstanding shares
         of Common Stock and shall be deemed to have been sold for cash in an
         amount equal to (1) any cash paid for such warrants, options or
         Convertible Securities plus (2) the price per share payable upon the
         exercise of such rights,

<PAGE>


         warrants or options or upon the conversion or exchange of such
         Convertible Securities issuable upon the exercise of such rights,
         warrants or options.

         (ii) In case the Company shall modify the rights of conversion,
         exchange or exercise of any of the securities referred to in (i) above
         or any other securities of the Company convertible, exchangeable or
         exercisable for shares of Common Stock, for any reason other than an
         event that would require adjustment to prevent dilution, so that the
         consideration per share received by the Company after such modification
         is less than XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX, the number of shares to
         be issued and outstanding shall be recalculated according to (i) and
         the number of antidilution shares issued pursuant to paragraph (c) or
         (d), as the case may be, shall be recalculated and any additional
         resulting antidilution shares shall thereupon be issued.

         (iii) In the case of the sale for cash of any shares of Common Stock,
         any Convertible Securities, any rights or warrants to subscribe for or
         purchase, or any options for the purchase of, Common Stock or
         Convertible Securities, the consideration received by the Company
         theretofor shall be deemed to be the gross sales price therefor without
         deducting therefrom any expense paid or incurred by the Company or any
         underwriting discounts or commissions or concessions paid or allowed by
         the Company in connection therewith.

                  (h) No adjustment in the Warrant Price shall be required
unless such adjustment would require an increase or decrease of at least five
cents ($0.05) in such price; provided, however, that any adjustments not
required to be made shall be carried forward and taken into account in any
subsequent adjustment. All calculations under this Section 4 shall be made to
the nearest cent or to the nearest one-thousandth of a share, as the case may
be.

                  (i) Anything in this Section 4 to the contrary
notwithstanding, the Company shall be entitled, but shall not be required, to
make such changes in the Warrant Price, in addition to those required by this
Section 4, as it in its discretion shall determine to be advisable in order that
any dividend or distribution in shares of Common Stock, subdivision,
reclassification or combination of shares of Common Stock, issuance of rights or
warrants to purchase Common Stock or distribution of shares of stock other than
Common Stock, evidences of indebtedness or assets (other than distributions in
cash out of retained earnings) referred to hereinabove in this Section 4,
hereafter made by the Company to the holders of its Common Stock shall not be
taxable to them.

                  (j) Whenever the Warrant Price is adjusted, as herein
provided, the Company shall promptly cause a notice setting forth the adjusted
Warrant Price and adjusted number of shares issuable upon exercise of this
Warrant to be mailed to the Holder. The certificate setting forth the
computation shall be signed by the Chief Financial Officer of the Company.

<PAGE>


                  (k) In the event that at any time, as a result of any
adjustment made pursuant to paragraph (a) above, the holder of this Warrant
thereafter shall become entitled to receive any shares of the Company, other
than Common Stock, thereafter the number of such other shares so receivable upon
exercise of this Warrant shall be subject to adjustment from time to time in a
manner and on terms as nearly equivalent as practicable to the provisions with
respect to the Common Stock contained in paragraphs (a) to (h) inclusive, above.

Section 5.        Rights and Obligations of the Warrant Holder.

         This Warrant shall not entitle the Holder to any rights of a
stockholder in the Company.

Section 6.        Restrictive Stock Legend.

         This Warrant and the Warrant Shares have not been registered under any
securities laws. Accordingly, until such time as the securities represented
thereby are no longer subject to the restrictions set forth in Section 4.2 of
the Purchase Agreement and there is delivered to the Company an opinion of
counsel reasonably acceptable to the Company to the effect that such legend is
no longer required, any stock certificates issued pursuant to the exercise of
this Warrant shall bear the following legend:

                  THIS SECURITY IS SUBJECT TO THE PROVISIONS OF THE AMENDED AND
                  RESTATED INVESTMENT AND MASTER STRATEGIC RELATIONSHIP
                  AGREEMENT DATED AS OF OCTOBER 9, 1997 BETWEEN THE ISSUER AND
                  SYNTHELABO AND MAY NOT BE SOLD OR TRANSFERRED EXCEPT IN
                  ACCORDANCE THEREWITH. A COPY OF SUCH AGREEMENT IS ON FILE AT
                  THE OFFICE OF THE CORPORATE SECRETARY OF THE ISSUER. THIS
                  SECURITY WAS SOLD IN A PRIVATE PLACEMENT, WITHOUT REGISTRATION
                  UNDER THE SECURITIES ACT OF 1933, AND MAY BE OFFERED OR SOLD
                  ONLY IF REGISTERED UNDER THE SECURITIES ACT OF 1933 OR IF AN
                  EXEMPTION FROM REGISTRATION IS AVAILABLE.

Section 7.        Notices.

         Any notice or other communication required or permitted to be given
here shall be in writing and shall be effective (a) upon hand delivery or
delivery by telex (with correct answerback received), telecopy or facsimile at
the address or number designated below (if delivered on a business day during
normal business hours where such notice is to be received), or the first
business day following such delivery (if delivered other than on a business day
during normal business hours where such notice is to be received) or (b) on the
third business day following the date of mailing by express courier service,
fully prepaid,

<PAGE>


addressed to such address, or upon actual receipt of such mailing, whichever
shall first occur. The addresses for such communication shall be:

         If to the Company:

         Angeion Corporation
         3650 Annapolis Lane, Suite 170
         Plymouth, MN 55447-5434
         Telephone: (612) 550-9388
         Telecopier: (612) 509-9525
         Attention: Chief Financial Officer

         With a copy to:

         Morrison & Foerster LLP
         425 Market Street
         San Francisco, CA 94105
         Telephone: (415) 268-7000
         Telecopier: (415) 268-7522
         Attention: Gavin B. Grover, Esq.

         If to the Holder:

         Synthelabo
         22 Avenue Galilee
         92350 Le Plessis Robinson
         France
         Telephone: (33)(1)45.37.56.67
         Telecopier: (33)(1)45.37.58.04
         Attention: General Counsel

         With copies to:

         ELA Medical
         Centre d'Affairs la Boursidiere
         92357 Le Plessis Robinson
         France
         Telephone: (33)(1)46.01.33.01
         Telecopier: (33)(1)46.01.33.15
         Attention: President

                and

         Coudert Brothers

<PAGE>


         1114 Avenue of the Americas
         New York, NY 10036-7703
         Telephone: (212) 626-4400
         Telecopier: (212) 626-4120
         Attention: James C. Colihan, Esq.

Each party hereto may from time to time change its address for notices under
this Section 7 by giving at least 10 days' notice of such changes address to the
other party hereto.

Section 8.        Amendments and Waivers.

         This Warrant and any term hereof may be changed, waived, discharged or
terminated only by an instrument in writing signed by the party against which
enforcement of such change, waiver, discharge or termination is sought.

Section 9.        Applicable Law.

         This Warrant shall be governed by and construed and enforced in
accordance with the laws of the State of New York.

Section 10.       Definitions.

         As used in this Warrant, the following terms shall be defined as
follows:

         "Fair Market Value Price" shall mean the average Quoted Price for the
five business days prior to the closing of the applicable sale.

         "Future Financing" shall mean any future offering of any shares of any
class of Company Securities with voting rights generally to elect directors of
the Company.

         "Initial Anti-Dilution Period" shall mean the period commencing on
October 9, 1997 and terminating on the XXXXXXXXXXXX of the date hereof.

         "Initial Reference Price" shall mean XXXXXXXXXXXXXXXXXXXXXXXX of the
average Quoted Price for all trading days within XXXXXXXXXXXXXXXXXX ending two
days prior to the public announcement by the Company of the transactions
contemplated by the Purchase Agreement.

         "Quoted Price" of the Common Stock shall mean: the last sale price
regular way or, in the case no such sale takes place on such day, the average of
the closing bid and asked prices regular way, in wither case on the NASDAQ
National Market System as reported by NASDAQ, or, if the Common Stock is not
authorized for quotation on the NASDAQ National Market System, on the New York
Stock Exchange Composite Tape (the "Composite Tape"), or, if the Common Stock is
not listed or admitted to trading on such exchange, on

<PAGE>


the national securities exchange in or nearest the City of New York on which the
Common Stock is listed or admitted to trading, or if the Common Stock is not
listed or admitted to trading on any national securities exchange, the last sale
price regular way or, in case no such sale takes place on such day, the average
of the highest reported bid and lowest reported asked prices as furnished by the
National Association of Securities Dealers Inc. through NASDAQ or a similar
organization if NASDAQ is no longer reporting such information, or if on any
such trading day the Common Stock is not quoted by any such organization, the
fair value of a share of Common Stock on such day, as determined in good faith
by the board of directors of the Company.

         IN WITNESS WHEREOF, the Company has caused this Warrant to be duly
executed on the day and year first above written.


                                         ANGEION CORPORATION



                                         By: /s/ Whitney A. McFarlin
                                             ---------------------------
                                             Title: Chairman/CEO

<PAGE>


                                    Exhibit A

To:  ANGEION CORPORATION


                              ELECTION TO EXERCISE

                  The undersigned hereby exercises its right to subscribe for
and purchase from ANGEION CORPORATION ______ fully paid, validly issued and
nonassessable shares of Common Stock covered by the within Warrant and tenders
payment herewith in the amount of $__________ in accordance with the terms
thereof, and requests that certificates for such shares be issued in the name
of, and delivered to:


                 ----------------------------

                 ----------------------------

                 ----------------------------


Date:                                     [Holder]
     ----------------------


                                          By 
                                             ----------------------------------
                                              Name:
                                              Title:

<PAGE>


                                    Exhibit B

                                 ASSIGNMENT FORM

To:   ANGEION CORPORATION

      The undersigned hereby assigns and transfers this Warrant to

--------------------------------------------------------------------------------
        (Insert assignee's social security or tax identification number)

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------
            (Print or type assignee's name, address and postal code)

and irrevocably appoints ______________________________________________________
to transfer this Warrant on the books of the Company.

Date:  ___________________                [Holder]



                                          By 
                                             ----------------------------------
                                              Name:
                                              Title:

         (Sign exactly as your name appears on the face of this Warrant)

Signature guarantee: